Neurogene Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Neurogene Inc. (NGNE) had Lessee, Operating Lease, Liability, to be Paid, Year One of $3.85 million as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-24
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $3.85M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $3.99M.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $3.99M.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $3.99M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $3.85M 10-K · filed 2026-03-24 |
| 2024-12-31 | $3.99M 10-K · filed 2025-03-24 |
| 2024-09-30 | $3.99M 10-Q · filed 2024-11-18 |
| 2024-06-30 | $3.99M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $3.99M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $3.86M 10-K · filed 2024-03-18 |
| 2022-12-31 | $2.72M 10-K · filed 2023-03-20 |
| 2021-12-31 | $2.66M 10-K · filed 2022-03-01 |
| 2020-12-31 | $2.16M 10-K · filed 2021-03-25 |
| 2019-12-31 | $570.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $207.00K 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |